196 related articles for article (PubMed ID: 18275813)
1. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
Li S; Kussie P; Ferguson KM
Structure; 2008 Feb; 16(2):216-27. PubMed ID: 18275813
[TBL] [Abstract][Full Text] [Related]
2. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.
Li S; Schmitz KR; Jeffrey PD; Wiltzius JJ; Kussie P; Ferguson KM
Cancer Cell; 2005 Apr; 7(4):301-11. PubMed ID: 15837620
[TBL] [Abstract][Full Text] [Related]
4. A molecular view of anti-ErbB monoclonal antibody therapy.
Leahy DJ
Cancer Cell; 2008 Apr; 13(4):291-3. PubMed ID: 18394550
[TBL] [Abstract][Full Text] [Related]
5. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
[TBL] [Abstract][Full Text] [Related]
6. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor.
Alvarenga ML; Kikhney J; Hannewald J; Metzger AU; Steffens KJ; Bomke J; Krah A; Wegener A
Anal Biochem; 2012 Feb; 421(1):138-51. PubMed ID: 22085444
[TBL] [Abstract][Full Text] [Related]
7. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies.
Donaldson JM; Zer C; Avery KN; Bzymek KP; Horne DA; Williams JC
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17456-61. PubMed ID: 24101516
[TBL] [Abstract][Full Text] [Related]
8. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.
Schmitz KR; Bagchi A; Roovers RC; van Bergen en Henegouwen PM; Ferguson KM
Structure; 2013 Jul; 21(7):1214-24. PubMed ID: 23791944
[TBL] [Abstract][Full Text] [Related]
9. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
[TBL] [Abstract][Full Text] [Related]
10. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.
Voigt M; Braig F; Göthel M; Schulte A; Lamszus K; Bokemeyer C; Binder M
Neoplasia; 2012 Nov; 14(11):1023-31. PubMed ID: 23226096
[TBL] [Abstract][Full Text] [Related]
11. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response.
Hartmann C; Müller N; Blaukat A; Koch J; Benhar I; Wels WS
Oncogene; 2010 Aug; 29(32):4517-27. PubMed ID: 20514015
[TBL] [Abstract][Full Text] [Related]
12. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
Herbst RS; Kim ES; Harari PM
Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
[TBL] [Abstract][Full Text] [Related]
13. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor.
Johns TG; Adams TE; Cochran JR; Hall NE; Hoyne PA; Olsen MJ; Kim YS; Rothacker J; Nice EC; Walker F; Ritter G; Jungbluth AA; Old LJ; Ward CW; Burgess AW; Wittrup KD; Scott AM
J Biol Chem; 2004 Jul; 279(29):30375-84. PubMed ID: 15075331
[TBL] [Abstract][Full Text] [Related]
14. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab: from bench to bedside.
Vincenzi B; Zoccoli A; Pantano F; Venditti O; Galluzzo S
Curr Cancer Drug Targets; 2010 Feb; 10(1):80-95. PubMed ID: 20088790
[TBL] [Abstract][Full Text] [Related]
16. Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope.
Makabe K; Yokoyama T; Uehara S; Uchikubo-Kamo T; Shirouzu M; Kimura K; Tsumoto K; Asano R; Tanaka Y; Kumagai I
Sci Rep; 2021 Mar; 11(1):5790. PubMed ID: 33707468
[TBL] [Abstract][Full Text] [Related]
17. Role of an anti-epidermal growth factor receptor in treating cancer.
Waksal HW
Cancer Metastasis Rev; 1999; 18(4):427-36. PubMed ID: 10855786
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight.
Covaceuszach S; Cattaneo A; Lamba D
Proteins; 2005 Feb; 58(3):717-27. PubMed ID: 15625712
[TBL] [Abstract][Full Text] [Related]
19. EGF receptor inhibition: attacks on multiple fronts.
Hubbard SR
Cancer Cell; 2005 Apr; 7(4):287-8. PubMed ID: 15837615
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]